Top Story Today
Vertex Bets $10 Billion That Hormones Are Biotech's Next Frontier
Vertex just made the biggest acquisition in its history, paying $10 billion in all cash for Crinetics Pharmaceuticals at a 102% premium. The prize: Palsonify, the first oral pill for acromegaly (a rare growth hormone disorder that previously required injections), plus a Phase 3 candidate for congenital adrenal hyperplasia with roughly $2 billion in projected peak sales. Together, the two drugs could generate over $5 billion annually, giving Vertex a fifth therapeutic pillar in endocrinology. The catch? The deal won't boost earnings until 2029.
Why it matters: This is Vertex declaring that its cystic fibrosis cash machine needs a running mate. A 102% premium resets the takeout price for every mid-cap rare disease biotech, and it signals that specialty endocrinology just became one of pharma's hottest competitive arenas.
Read more →The ADC Arms Race
Gilead Pays Up to $5B for a Munich Startup That Raised €10.7M Six Years Ago
Gilead is acquiring Tubulis, a German ADC platform company, for $3.15 billion upfront plus $1.85 billion in milestones. Tubulis has zero approved products; what it does have is proprietary linker chemistry that produces ultra-stable antibody-drug conjugates. Combined with the recent Arcellx deal, Gilead has committed roughly $13 billion to oncology acquisitions in a compressed window. The HIV giant is going all-in on cancer.
Read more →Novartis Drops $1.1B on a Company With Zero Human Data
Novartis paid $1.1 billion upfront (plus $400 million in milestones) for UK startup Myricx Bio, whose ADC payloads use a completely novel mechanism called NMT inhibition. In preclinical models, the payloads caused complete tumor regression where existing ADCs failed. It's Novartis's formal entry into oncology ADCs, and the company is betting it can leapfrog the current generation by skipping straight to next-gen payload chemistry.
Read more →Clinical and Regulatory
Sarepta's Worst Week: Black Box Warning, 500 Layoffs, No Easy Answers
After fatal liver failures in pediatric patients, Sarepta added the FDA's most severe warning to its Duchenne gene therapy Elevidys and pulled its non-ambulatory indication entirely. Then it cut 500 workers (36% of staff) to save $400 million annually. The drug generated $899 million last year, but 2026 guidance dropped to a $500 million floor. Analysts are split, with price targets ranging from $5 to $38 on a $19 stock.
Read more →The First Drug That Could Actually Treat Ataxia-Telangiectasia
IntraBio's pivotal trial for levacetylleucine in ataxia-telangiectasia hit its primary endpoint with p < 0.001, showing nearly two points of improvement on the SARA ataxia scale in just 12 weeks. For a progressive disease with zero approved treatments, any improvement is remarkable. The FDA granted Priority Review with a decision date of September 19, 2026.
Read more →Doctors Sue the CDC Over Its Childhood Vaccine Schedule Overhaul
Seven major medical groups, led by the American Academy of Pediatrics, are suing to overturn the CDC's decision to cut universal childhood vaccine recommendations from 17 diseases to 11. A federal judge already blocked the changes. At least 23 states have declared they'll follow the old schedule instead, creating a confusing patchwork for parents and pediatricians nationwide.
Read more →Deals, IPOs, and Earnings
Genentech Cut 103 Scientists and Signed a $490M Deal on the Same Day
Genentech laid off 103 researchers from its legendary gRED unit (shutting down its infectious disease and physiological chemistry groups entirely) while simultaneously inking a $490 million breast cancer collaboration with Astex. It's the clearest example yet of big pharma's 2026 playbook: shrink internal R&D, import innovation from partners, and concentrate on fewer high-conviction bets.
Read more →The Gene Editing Company That Wants to Replace Your Cholesterol Meds
Scribe Therapeutics, co-founded by Nobel laureate Jennifer Doudna, filed to go public seeking $75 million. Its lead candidate silences the PCSK9 gene without cutting DNA, potentially replacing daily statin pills with a single dose. In monkeys, one treatment sustained LDL-C reduction for roughly 18 months. Pharma partners Lilly, Sanofi, and Biogen have already committed billions in potential milestones.
Read more →J&J Shrugged Off the Government's Drug Pricing Hammer
The Most Favored Nation pricing policy was supposed to squeeze Big Pharma. J&J raised its 2026 forecast anyway, projecting $100.8 billion in revenue and roughly 7% profit growth. Management called MFN a "hundreds of millions" headwind, but blockbuster growth from Darzalex (hitting $4 billion per quarter) and Tremfya more than offset the hit.
Read more →